Moleculin Biotech +10% on receiving Orphan Drug status for brain tumor drug

|About: Moleculin Biotech, Inc. (MBRX)|By:, SA News Editor

The FDA has granted Orphan Drug status to Moleculin Biotech's (NASDAQ:MBRX) WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor.

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

Shares are up 10% premarket.

Subscribe for full text news in your inbox